Cefepime-Zidebactam Shows High Cure Rates in Phase 2 Trial

A prospective, open-label, single-arm phase 2 trial evaluated intravenous cefepime-zidebactam in adults with carbapenem-resistant Gram-negative infections, most caused by metallo-beta-lactamase-producing pathogens. Investigator-assessed clinical cure at test-of-cure was 91.7% in the evaluable population (86.7% by external adjudication), with 28-day mortality of 2.8% and treatment-related adverse events in 15.3% of participants. The trial reports these findings as evidence of activity against pathogens for which treatment options are limited, including NDM-beta-lactamase producers.

Most relevant for: Adults with infections caused by carbapenem-resistant Gram-negative bacteria, including metallo-beta-lactamase and NDM-producing organisms, particularly those with complicated urinary tract infections.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.